Shots:

• The US FDA has approved the BLA filing for Jemperli for adult patients with dMMR recurrent or advanced solid tumors endometrial cancer- as determined by an FDA-approved test- that has progressed on or following prior treatment with a Pt.-containing regimen
• AnaptysBio has received $20M as milestones upon the FDA’s approval and will receive $45M as regulatory milestones in the US & EU- $165M as sales milestones following achievement of annual sales revenues with royalties range from 8% to 25% of global sales
• Jemperli is currently being evaluated in P-III trials for recurrent or primary advanced EC and stage III or IV non-mucinous epithelial ovarian cancer and is the first AnaptysBio-generated Ab out of 8 to obtain FDA approval

  Ref: Globe Newswire | Image: GSK